- | Country : -
- | organs : -
- | Specialty : -
Extract
The primary objective of this study is to demonstrate the superiority of ODM-201 vs. placebo in metastasis free survival (MFS) in patients with high-risk nmCRPC
Inclusion criteria
- High-risk, non-metastatic castration-resistant prostate cancer (MedDRA: hormonerefractory prostate cancer),cancro della prostata resistente alla castrazione non metastatico ad alto rischio (MedDRA: cancro alla prostata ormone refrattario)